Cyclohexanecarboxylic acid, 4-(aminomethyl)-, hydrochloride, trans- | 3667-39-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Cyclohexanecarboxylic acid, 4-(aminomethyl)-, hydrochloride, trans-
• 英文别名: Kabi 2161；tranexamic acid hydrochloride；trans-4-(aminomethyl)cyclohexylcarboxylic acid hydrochloride；trans-4-(aminomethyl)cyclohexanecarboxylic acid hydrochloride；tranexamic acid*HCl；trans-4-Aminomethyl-cyclohexancarbonsaeure; Hydrochlorid
• CAS: 3667-39-8
• 化学式: C₈H₁₅NO₂*ClH
• 分子量: 193.674
• InChiKey: UGECKKSVDQIZQG-MEZFUOHNSA-N

物化性质

• 熔点：
  238.0-241.5 °C

计算性质

• 辛醇/水分配系数(LogP)：
  1.26
• 重原子数：
  12.0
• 可旋转键数：
  2.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  63.32
• 氢给体数：
  2.0
• 氢受体数：
  2.0

反应信息

• 作为反应物：
  描述：

  Cyclohexanecarboxylic acid, 4-(aminomethyl)-, hydrochloride, trans- 在 potassium carbonate 作用下， 以 乙醇 、 氯仿 为溶剂， 反应 42.0h， 生成
  参考文献：
  名称：

  Gd-Complexes of 1,4,7,10-Tetraazacyclododecane-N,N′,N′′,N′′′-1,4,7,10-tetraacetic Acid (DOTA) Conjugates of Tranexamates as a New Class of Blood-Pool Magnetic Resonance Imaging Contrast Agents

  摘要：

  Gd-complexes of the type [Gd(L)(H2O)] xH(2)O (5a-c), where Lis DOTA conjugates of tranexamic acid (4a) and tranexamic esters (4b,c), have been prepared as a new class of MRI blood-pool contrast agents (BPCAs) Thermodynamic stability (K-GdL) and pharmacokinetic inertness of 5 compare well with or better than those of analogous MRI contrasting agents (CAs) such as Gd-DOTA and Gd-DTPA-BMA Their R-1-relaxivities are significantly higher than those of any of the clinically used MRI CAs T-1-weighted MR images of mice administered by 5c demonstrate high blood-pool effect with simultaneous contrast enhancement in liver The structural uniqueness of 5c lies in the fact that it adopts macrocyclic DOTA instead of acyclic DTPA In addition, 5c is nonionic and makes no resort to aromatic substituent() in the chelate backbone for the blood-pool enhancement The nature of hepatobiliary uptake demonstrated by 5c may be explained in terms of lipophilicity of tranexamate in the chelate (4c) The cell cytotoxicity test shows no toxicity found with 5, suggesting their use as a practical MRI BPCAs

  DOI：

  10.1021/jm100966t
• 作为产物：
  描述：

  4-Azidomethyl-cyclohexanecarboxylic acid 在 palladium on activated charcoal 氢气 作用下， 以 盐酸 为溶剂， 以70%的产率得到Cyclohexanecarboxylic acid, 4-(aminomethyl)-, hydrochloride, trans-
  参考文献：
  名称：

  Lipase-mediated route to diastereo-pure tranexamic acid.

  摘要：

  利用脂肪酶 PS（假单胞菌 Amino）对 1，4-环己烷二甲醇的反式/顺式混合物进行非对映异构体分离，制备出非对映异构体纯氨甲环酸。

  DOI：

  10.1248/cpb.43.529

文献信息

• Aminocarboxylic acids, amino alcohols, or the derivatives thereof,
  申请人：Teijin Limited

  公开号：US04402975A1

  公开（公告）日：1983-09-06

  A compound represented by the following formula ##STR1## wherein R.sup.1 represents a hydrogen atom, an acyl group or an alkoxycarbonyl group; X.sup.1 represents an alkylene group having 3 to 6 carbon atoms, a 1,4-cyclohexylene group, or a 1,4-phenylene group, the alkylene group may be substituted by an alkyl group having 1 to 6 carbon atoms, and the 1,4-phenylene group may be substituted by 1 or 2 substituents selected from halogen atoms and alkoxy groups having 1 to 6 carbon atoms; R.sup.2 represents a hydrogen atom or a hydroxyl group and R.sup.3 represents hydrogen atom, or R.sup.2 and R.sup.3 together may form an oxo group (.dbd.O), and when X.sup.1 is other than the 1,4-phenylene group, R.sup.2 represents a hydrogen atom and R.sup.3 represents a bond between the carbon atoms to which R.sup.3 is bonded and that carbon atom of X.sup.1 which is adjacent to said carbon atom; X.sup.2 represents an alkylene group having 1 to 5 carbon atoms which may be substituted by an alkyl group having 1 to 6 carbon atoms or an amino group; and R.sup.4 represents the group --COOR.sup.5, --CH.sub.2 OR.sup.6 or --CONR.sup.7 R.sup.8 in which R.sup.5 represents a hydrogen atom or an alkyl group having 1 to 6 carbon atoms, R.sup.6 represents a hydrogen atom or an acyl group having 1 to 6 carbon atoms, and R.sup.7 and R are identical or different and represent a hydrogen atom or an alkyl group having 1 to 6 carbon atoms or taken together may form a 5- or 6-membered ring; or an acid addition salts of said compound wherein R.sup.1 represents a hydrogen atom or X.sup.2 represents an alkylene group having an amino group, or salts of said compound wherein R.sup.5 represents a hydrogen atom. The compounds represented by the above formula or their pharmaceutically acceptable salts are useful as anti-ulcer agents. The present invention also provides a process for producing the compounds or their pharmaceutically acceptable salts, which comprises acylating a protected derivative at the amino group of a corresponding acid halide with a corresponding substituted benzene in the presence of a Lewis acid; or reducing a corresponding compound in the presence of an inert solvent under conditions which induce reduction of the carbonyl group of said corresponding compound without substantially reducing the phenylene group of said corresponding compound; or dehydrating a corresponding compound.

  该化合物由以下公式表示##STR1## 其中R.sup.1代表氢原子、酰基或烷氧羰基；X.sup.1代表具有3至6个碳原子的烷基基团、1,4-环己基基团或1,4-苯基基团，该烷基基团可被具有1至6个碳原子的烷基基团取代，而1,4-苯基基团可被1或2个卤原子和具有1至6个碳原子的烷氧基团中选择的取代基所取代；R.sup.2代表氢原子或羟基，R.sup.3代表氢原子，或R.sup.2和R.sup.3一起可以形成氧羰基(.dbd.O)，当X.sup.1不是1,4-苯基基团时，R.sup.2代表氢原子，R.sup.3代表与R.sup.3结合的碳原子和X.sup.1中邻近所述碳原子之间的键；X.sup.2代表具有1至5个碳原子的烷基基团，该基团可被具有1至6个碳原子的烷基基团或氨基取代；R.sup.4代表基团--COOR.sup.5、--CH.sub.2 OR.sup.6或--CONR.sup.7 R.sup.8，其中R.sup.5代表氢原子或具有1至6个碳原子的烷基基团，R.sup.6代表氢原子或具有1至6个碳原子的酰基，而R.sup.7和R是相同或不同，代表氢原子或具有1至6个碳原子的烷基基团，或者一起形成一个5-或6-成员环；或者该化合物的酸盐，其中R.sup.1代表氢原子或X.sup.2代表具有氨基的烷基基团，或者该化合物的盐，其中R.sup.5代表氢原子。上述公式所表示的化合物或其药用盐作为抗溃疡剂是有用的。本发明还提供了一种制备该化合物或其药用盐的方法，包括在路易斯酸存在下，通过使相应酸卤衍生物在相应取代苯存在下酰化相应酸卤衍生物的氨基基团；或者在惰性溶剂存在下还原相应化合物，在诱导还原所述相应化合物的羰基但几乎不还原所述相应化合物的苯基团的条件下；或者脱水相应化合物。
• Gd-complexes of DTPA-bis(amide) conjugates of tranexamic acid and its esters with high relaxivity and stability for magnetic resonance imaging
  作者：Sujit Dutta、Ji-Ae Park、Jae-Chang Jung、Yongmin Chang、Tae-Jeong Kim

  DOI：10.1039/b719440d

  日期：——

  The synthesis and the characterization of a series of DTPA-bis(amide) conjugates of tranexamic acid (L1), its esters (L2–L6), and their Gd(III) complexes of the type [Gd(L)(H2O)]·nH2O (L = L1–L6) are described. Except for the case of L1, all Gd-complexes exhibit greatly enhanced R1 relaxivity. Highest R1 reaches up to 12.9 mM−1 s−1 for [Gd(L2)(H2O)]. Such high relaxivity is reflected in the intensity enhancement of the in vivoMRI study on H-ras transgenic mice bearing hepatic tumor when employing [Gd(L2)(H2O)] as an MRI contrast agent. Thermodynamic stability constants, conditional stability constants, and the pM values demonstrate higher stability of [Gd(L)(H2O)]·nH2O (L = L1–L6) than Omniscan® under physiological conditions. The MTT assay performed on these complexes reveals cytotoxicity as low as that for Omniscan® in the concentration range required to obtain intensity enhancement in the in vivoMRI study.

  本文介绍了一系列氨甲环酸（L1）的 DTPA 双（酰胺）共轭物、其酯类（L2-L6）以及它们的[Gd(L)(H2O)]-n （L = L1-L6）型钆（III）络合物的合成和表征。除 L1 外，所有钆络合物的 R1 弛豫性都大大增强。[Gd(L2)( )]的 R1 最高可达 12.9 mM-1 s-1。使用[Gd(L2)( )]作为磁共振成像造影剂对携带肝肿瘤的 H-ras 转基因小鼠进行体内磁共振成像研究时，其强度增强反映了这种高弛豫性。热力学稳定常数、条件稳定常数和 pM 值表明，在生理条件下，[Gd(L)( )]-n （L = L1-L6）的稳定性高于 Omniscan®。对这些复合物进行的 MTT 分析表明，在体内磁共振成像研究中获得强度增强所需的浓度范围内，其细胞毒性与 Omniscan® 一样低。
• Trans-4-aminomethylcyclohexane-1-carboxylic acid
  申请人：Mitsubishi Chemical Industries Ltd.

  公开号：US03950405A1

  公开（公告）日：1976-04-13

  A trans isomer of 4-cyanoncyclohexane-1-carboxylic acid or its lower alkyl ester is reduced in a solvent in the presence of a hydrogenating catalyst, and hydrolyzing the produced ester in case the starting trans-isomer is a lower alkyl ester, then the trans-4-aminomethyl-cyclohexane-1-carboxylic acid is recovered from the reaction mixture.

  在溶剂中，存在氢化催化剂的情况下，将4-氰基环己烷-1-羧酸或其较低的烷基酯的顺式异构体还原，并在起始顺式异构体为较低的烷基酯的情况下水解产生的酯，然后从反应混合物中回收顺式-4-氨甲基环己烷-1-羧酸。
• MOUTHWASH COMPOSITION FOR PREVENTING AND/OR TREATING PERIODONTAL DISEASES
  申请人：HAYASHIBARA CO., LTD.

  公开号：US20140356298A1

  公开（公告）日：2014-12-04

  The present invention has an object to provide a mouthwash composition for preventing and/or treating periodontal diseases safely and effectively. The present invention solves the above object by providing a mouthwash composition for preventing and/or treating periodontal diseases, characterized in that it comprises, as an effective ingredient(s), one or more members selected from the group consisting of adenosine N1-oxide, 3′-glucosyladenosine N1-oxide, 5′-glucosyladenosine N1-oxide, 5′-adenosine diphosphate N1-oxide, and 5′-adenosine triphosphate N1-oxide but does not contain any saccharide assimilable by periodontal disease bacteria.

  本发明的目的是提供一种安全有效的口腔清洗剂组合物，用于预防和/或治疗牙周疾病。本发明通过提供一种口腔清洗剂组合物来解决上述问题，其特征在于其包含一种或多种从腺苷N1-氧化物、3'-葡萄糖基腺苷N1-氧化物、5'-葡萄糖基腺苷N1-氧化物、5'-腺苷二磷酸N1-氧化物和5'-腺苷三磷酸N1-氧化物组成的有效成分，但不含任何牙周疾病细菌可吸收的糖类。
• ORAL WASHING COMPOSITION FOR PREVENTING AND/OR TREATING PERIODONTAL DISEASES
  申请人：Hayashibara Co., Ltd.

  公开号：EP2801348B1

  公开（公告）日：2019-05-22